Works matching IS 11707690 AND DT 2021 AND VI 39 AND IP 8

Results: 11

Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening.

Published in:

2021

By:

Keeney, Edna;
Thom, Howard;
Turner, Emma;
Martin, Richard M.;
Sanghera, Sabina

Publication type:

Letter

Comment on Keeney et al.'s "Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening".

Published in:

2021

By:

O'Mahony, James F.

Publication type:

Letter

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals.

Published in:

PharmacoEconomics, 2021, v. 39, n. 8, p. 869, doi. 10.1007/s40273-021-01034-5

By:

Srivastava, Tushar;
Latimer, Nicholas R.;
Tappenden, Paul

Publication type:

Article

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.

Published in:

PharmacoEconomics, 2021, v. 39, n. 8, p. 913, doi. 10.1007/s40273-021-01026-5

By:

Pennington, Becky;
Alshreef, Abualbishr;
Flight, Laura;
Metry, Andrew;
Poku, Edith;
Hykin, Philip;
Sivaprasad, Sobha;
Prevost, A. Toby;
Vasconcelos, Joana C.;
Murphy, Caroline;
Kelly, Joanna;
Yang, Yit;
Lotery, Andrew;
Williams, Michael;
Brazier, John

Publication type:

Article

Retraction Note to: The EQ-5D-5L Valuation Study in Egypt.

Published in:

PharmacoEconomics, 2021, v. 39, n. 8, p. 971, doi. 10.1007/s40273-021-01055-0

By:

Al Shabasy, Sahar A.;
Abbassi, Maggie M.;
Finch, Aureliano Paolo;
Baines, Darrin;
Farid, Samar F.

Publication type:

Article

Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.

Published in:

2021

By:

To, Yat Hang;
Degeling, Koen;
Kosmider, Suzanne;
Wong, Rachel;
Lee, Margaret;
Dunn, Catherine;
Gard, Grace;
Jalali, Azim;
Wong, Vanessa;
IJzerman, Maarten;
Gibbs, Peter;
Tie, Jeanne

Publication type:

journal article

Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies.

Published in:

PharmacoEconomics, 2021, v. 39, n. 8, p. 879, doi. 10.1007/s40273-021-01045-2

By:

Duarte, Ana;
Walker, Simon;
Metry, Andrew;
Wong, Ruth;
Panovska-Griffiths, Jasmina;
Sculpher, Mark

Publication type:

Article

Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries.

Published in:

2021

By:

Williams, Kate;
Aggio, Daniel;
Chen, Peter;
Anokhina, Katerina;
Lloyd, Andrew J.;
Wang, Yan

Publication type:

journal article

A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.

Published in:

PharmacoEconomics, 2021, v. 39, n. 8, p. 929, doi. 10.1007/s40273-021-01033-6

By:

McDool, Emily;
Mukuria, Clara;
Brazier, John

Publication type:

Article

Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector.

Published in:

2021

By:

Pokhilenko, Irina;
Janssen, Luca M. M.;
Evers, Silvia M. A. A.;
Drost, Ruben M. W. A.;
Schnitzler, Lena;
Paulus, Aggie T. G.

Publication type:

research

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.

Published in:

2021

By:

Nilsson, Fredrik O. L.;
Asanin, Sandra T.;
Masters, Elizabeth T.;
Iadeluca, Laura;
Almond, Chrissy;
Cooper, Miranda;
Smith, Sarah

Publication type:

journal article